May 02, 2022 3:57pm EDT MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
Mar 31, 2022 10:03pm EDT Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update
Mar 31, 2022 3:45pm EDT Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement
Mar 24, 2022 7:30am EDT Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
Mar 01, 2022 7:30am EST Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study
Feb 16, 2022 7:30am EST Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
Feb 08, 2022 7:30am EST Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada